Contraindication to surgery in primary retroperitoneal sarcoma: Retrospective series on 20 years of practice in a high-volume sarcoma center - 17/04/25
Summary |
Introduction |
Surgery is the cornerstone treatment for retroperitoneal sarcomas (RPS). However, contraindications for unresectability are not well-documented in the literature.
Aim of the study |
This study aims to identify contraindications that prevent surgery for primary RPS in a high-volume sarcoma center.
Methods |
We retrospectively analyzed all consecutive patients treated for primary RPS at our center from 1995 to 2021.
Results |
Among the 452 patients treated for primary RPS, 92 (20%) were not offered surgery. The reasons for unresectability were categorized as follows: poor general health or severe comorbidities in 39 patients (42%), preoperative detection of distant metastases in 33 patients (36%), and locally advanced disease in 20 patients (22%). Locally advanced disease included vascular involvement in 14 patients (15%) and vertebral invasion in 6 patients (7%). Among the non-operated patients, 66% received chemotherapy, 16% received radiotherapy, and 5% received combined treatments. The median progression-free survival was 7months, and the median overall survival was 18months. The 1-year overall survival rate was 53%.
Conclusion |
Contraindications for surgery in patients with primary RPS in a high-volume sarcoma center are not uncommon. The next step should be to differentiate absolute from relative (i.e., preoperative modifiable factors) contraindications.
Le texte complet de cet article est disponible en PDF.Keywords : Retroperitoneal sarcoma, Sarcoma network, Surgery, Unresectable, Selection, Contraindication
Plan
Vol 162 - N° 2
P. 111-116 - avril 2025 Retour au numéro
Article précédent
- What is the best management of patients after percutaneous transhepatic gallbladder drainage for acute lithiasic cholecystitis? Comparison of two different strategies
- Fanny Sok, François Mauvais, Marion Demouron, Thierry Yzet, Noémie Ammar-Khodja, Jean-Marc Regimbeau
- Management of pilonidal sinus and recurrences in 2025
- Benjamin Darnis, Louise Tedeschi, Marie-Cécile Blanchet, Vincent Frering, Jessica Crozet, Benoit Gignoux, Christophe Duchamp
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?